Considerations in the developability of peptides for oral administration when formulated together with transient permeation enhancers.

Berg, Staffan; Edlund, Helena; R F Goundry, William; A S Bergström, Christel; Davies, Nigel M

Berg, Staffan; Edlund, Helena; R F Goundry, William; A S Bergström, Christel; Davies, Nigel M.

Afiliação

Berg S; Advanced Drug Delivery, Pharmaceutical Science, R&D, AstraZeneca, Gothenburg, Sweden; The Swedish Drug Delivery Center, Department of Pharmacy, Uppsala University, Biomedicinskt Centrum, Uppsala, Sweden.
Edlund H; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
R F Goundry W; Early Chemical Development, Pharmaceutical Science, R&D, AstraZeneca, Macclesfield, United Kingdom.
A S Bergström C; The Swedish Drug Delivery Center, Department of Pharmacy, Uppsala University, Biomedicinskt Centrum, Uppsala, Sweden.
Davies NM; Advanced Drug Delivery, Pharmaceutical Science, R&D, AstraZeneca, Gothenburg, Sweden. Electronic address: nigel.davies@astrazeneca.com.

Int J Pharm ; 628: 122238, 2022 Nov 25.

Article em En | MEDLINE | ID: mdl-36174850

Assuntos

Sistemas de Liberação de Medicamentos; Peptídeos; Administração Oral; Peptídeos/química; Disponibilidade Biológica; Meia-Vida

Palavras-chave

Bioavailability; Oral peptide delivery; Peptide properties; Permeation enhancer; Population pharmacokinetic modelling; Variability

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Peptídeos / Sistemas de Liberação de Medicamentos Idioma: En Revista: Int J Pharm Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Suécia

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google